Gate Bioscience expands Lilly drug discovery deal worth more than $870 million

Gate Bioscience said on Monday it expanded a research and licensing ​agreement with Eli Lilly to develop ‌treatments targeting disease-causing proteins, in a deal potentially worth more than $870 mill...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。